The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic
drugs (DMARDs) is an evolving area. A systematic review of Scopus, Web of Science …

Takayasu arteritis is an idiopathic granulomatous vasculitis of the aorta and its main
branches and it constitutes one of the more common vasculitides in children. Inflammation …

Objective To investigate the efficacy and safety of the interleukin-6 receptor antibody
tocilizumab in patients with Takayasu arteritis (TAK). Methods Patients with TAK who had …

Objective Tumor necrosis factor (TNF) alpha and interleukin‐17 (IL‐17) are thought to be
involved in the pathogenesis of Takayasu arteritis (TAK), and TNF inhibitors (TNFi) are …

The C-Reactive Protein/Albumin Ratio and Complete Blood Count Parameters as Indicators of
Disease Activity in Patients with Takayasu Arteritis - PMC Back to Top Skip to main content NIH …

The term “vasculitis” refers to a group of rare immune‐mediated diseases characterized by
the dysregulated immune system attacking blood vessels located in any organ of the body …

Objective Takayasu's arteritis (TAK) is a large vessel vasculitis with important infiltration of
proinflammatory T cells in the aorta and its main branches, but its aetiology is still unknown …

The involvement of IL-17A in autoimmune and inflammatory diseases has prompted the
development of therapeutic strategies to block the Th17 pathway. Promising results came …

Arterial wall damage in Takayasu arteritis (TAK) can progress despite immunosuppressive
therapy. Vascular fibrosis is more prominent in TAK than in giant cell arteritis (GCA). The …

Purpose We evaluated T helper lymphocyte profile, including novel Th17 subsets Th17. 1
(secrete IFN-γ, associate with corticosteroid resistance) and PD1+ Th17 (secrete TGF-β1 …